Purdue Pharma’s Latest Settlement: A New Chapter in the Opioid Crisis
In a significant development in the ongoing legal battles over the opioid crisis, a federal bankruptcy judge has given the green light to Purdue Pharma’s revised settlement plan. This new agreement, involving the makers of OxyContin, aims to resolve thousands of lawsuits by providing financial compensation to victims of the opioid epidemic.
U.S. Bankruptcy Judge Sean Lane has agreed to the settlement, which requires the Sackler family, owners of Purdue Pharma, to contribute up to $7 billion over the next 15 years. This new settlement replaces a previously rejected agreement by the U.S. Supreme Court, which had found issues regarding legal protections for the Sacklers against future lawsuits. Judge Lane is expected to further elaborate on his decision in an upcoming hearing.
The settlement is a major step in a long series of legal actions by state and local governments against various entities in the pharmaceutical industry. These lawsuits have targeted drug manufacturers, distributors, and pharmacies, seeking accountability for the opioid crisis, which has been linked to approximately 900,000 deaths in the U.S. since 1999.
Purdue’s legal proceedings have been notably complex, involving numerous stakeholders, including attorneys representing states, cities, counties, Native American tribes, and individuals affected by addiction. The consensus among these groups has been to support the bankruptcy plan, which Purdue filed for six years ago amid mounting legal claims.
Marshall Huebner, a lawyer representing Purdue, expressed the limitations of the settlement, stating, “The plan is entirely lawful, does the greatest good for the greatest number in the shortest available timeframe.” He acknowledged the inability to provide compensation equivalent to the immense suffering caused by the crisis.
Muted Opposition and New Legal Provisions
This time, dissent against the settlement has been relatively quiet. Unlike the previous deal, the new arrangement allows entities not opting into the settlement to pursue lawsuits against the Sackler family. The family’s assets, largely held in offshore trusts, remain challenging to access through legal means.
Of the more than 54,000 personal injury victims who voted on the plan, only 218 opposed it, with many choosing not to vote. Notably, there were no protests outside the courthouse during the proceedings.
Some objectors argued for criminal liability for the Sacklers, which Judge Lane noted was outside the scope of bankruptcy court. Others contended that settlement funds should go directly to victims rather than government entities.
Implications and Future Steps
The settlement will see Purdue Pharma undergo significant changes, including a rebranding to Knoa Pharma and the transfer of ownership to new overseers committed to funding efforts against the opioid crisis. This transition could take place by spring 2026.
As part of the agreement, the Sackler family will be barred from involvement in opioid-related businesses globally, and their names will not be used for charitable recognition. Company documents, including those typically protected by attorney-client privilege, will be made public.
Compensation for Individual Victims
Unlike other opioid settlements, this agreement provides for individual compensation. Approximately $850 million is allocated for victims, with over $100 million dedicated to helping children born with opioid withdrawal symptoms. Payments to individual victims are expected next year.
Christopher Shore, representing individual victims, noted the pragmatic benefits of the settlement over litigation against the Sacklers. He stated, “Some Sacklers are bad people, but the reality is that sometimes bad people win in litigation.”
The bulk of the settlement funds are earmarked for state and local governments to bolster their efforts in combating the opioid crisis, contributing to recent declines in overdose deaths, a trend partially attributed to the impact of such settlement funds.
This article was originally written by www.npr.org
